middle.news
Mesoblast Posts US$115M Ryoncil Revenue as Adult Trials and CAR Tech Advance
10:01am on Thursday 30th of July, 2026 AEST
•
Healthcare
Read Story
Mesoblast Posts US$115M Ryoncil Revenue as Adult Trials and CAR Tech Advance
10:01am on Thursday 30th of July, 2026 AEST
Key Points
Ryoncil® nets US$36 million in Q4 and US$115 million full-year revenue
Adult steroid-refractory acute GvHD trial underway with 40 US sites
Phase 3 chronic low back pain trial reaches 300-patient target
US$50 million drawn from five-year facility to retire maturing debt
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE